Risk Factor Number and Recurrence, Metastasis, and Disease-Related Death in Cutaneous Squamous Cell Carcinoma
JAMA Dermatology · 01.06.2025 · 161 (6) · 597
DOI: 10.1001/jamadermatol.2025.0128 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift JAMA Dermatology, erschienen am 01.06.2025. Verfasst von Nina A Ran und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Brigham and Women's Hospital, Boston, Massachusetts. Hauptthemen laut MEDLINE: Skin Neoplasms, Neoplasm Recurrence, Local, Carcinoma, Squamous Cell. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Importance Cutaneous squamous cell carcinoma (CSCC) risk stratification is central to management, and physicians rely on tumor staging systems to estimate risk. The Brigham and Women’s Hospital (BWH) T staging system predicts risk based on 4 tumor risk factors (RFs). However, stage is not precisely associated with the number of RFs, as BWH stage T2b includes CSCCs with 2 and 3 RFs.
Objective
To determine how RF number is associated with the risk of recurrence, metastasis, and disease-related death. Design, Setting, and Participants This retrospective multination cohort study of CSCCs diagnosed between October 1, 1991, and July 19, 2023, was conducted at 12 centers in the US (10), Spain (1), and Brazil (1). Invasive CSCCs with confirmed negative margins longer than 14 days were included. Tumors were excluded if they were metastatic at presentation or received adjuvant therapy. Data were analyzed from October 2023 to August 2024. Interventions or Exposures CSCCs were stratified by the number of the following RFs (0, 1, 2, 3, or 4): a diameter of 2 cm or larger, poorly differentiated histology, tumor extension beyond subcutaneous fat, and large caliber nerve invasion. Main Outcomes and Measures Five-year cumulative incidences of local recurrence, nodal metastasis, distant metastasis, and disease-specific death.
Results
A total of 16 844 CSCCs were included (5978 female individuals [35.5%]; median [IQR] age, 73.9 [65.7-81.8] years), with 0 (12 657 [75.1%]), 1 (2892 [17.2%]), 2 (1015 [6.0%]), 3 ( 225 [1.3%]) or 4 (55 [0.3%]) RFs. Median (IQ) follow up time was 33.6 (14.5-60.3) months. For local recurrence, the risk increased as the number of RF increased from 0 (1.7%; 95% CI, 1.5%-2.0%) to 1 (5.0%; 95% CI, 4.1%-5.9%) to 2 (8.8%; 95% CI, 7.0%-11.0%) to 3 (16.0%; 95% CI, 11.0%-22.0%) to 4 (33.0%; 95% CI, 19.0%-47.0%; P < .001 for between-group differences). This increase was also observed for nodal metastasis (0.6% [95% CI, 0.4%-0.7%] vs 3.6% [95% CI, 2.9%-4.4%] vs 11.0% [95% CI, 9.2%-13.0%] vs 20.0% [95% CI, 15.0%-26.0%] vs 28.0% [95% CI, 15.0%-42.0%], respectively; P < .001), distant metastasis (0.2% [95% CI, 0.1%-0.3%] vs 1.1% [95% CI, 0.7%-1.6%] vs 2.3% [95% CI, 1.4%-3.4%] vs 7.9% [95% CI, 4.6%-12.0%] vs 8.4% [95% CI, 2.6%-19.0%], respectively; P < .001), and disease-specific death (0.3% [95% CI, 0.2%-0.4%] vs 1.9% [95% CI, 1.4%-2.7%] vs 5.4% [95% CI, 4.0%-7.0%] vs 11.0% [95% CI, 6.7%-16.0%] vs 25% [95% CI, 12%-39%], respectively; P < .001). CSCCs with 3 RFs had higher cumulative incidences of local recurrence (1.6-fold), nodal metastasis (1.9-fold), distant metastasis (4.3-fold), and disease-specific death (1.9-fold) compared with those with 2 RFs. Conclusions and Relevance The results of this cohort study suggest that the number of RFs is an indicator of risk, and among BWH T2b tumors, those with 3 RFs represent a higher risk subset.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Dermatology, Brigham and Women's Hospital, Boston, Massachusetts.
- Department of Medicine, Newton-Wellesley Hospital, Boston, Massachusetts.
- Zitelli and Brodland P.C., Pittsburgh, Pennsylvania.
- Department of Dermatology, Complejo Asistencial Universitario de Salamanca, Salamanca, Spain.
- Department of Dermatology, The Ohio State University Medical Center, Columbus.
- Department of Dermatology, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire.
Zitieren
APA
Ran, N. A., Granger, E. E., Brodland, D. G., Cañueto, J., Carr, D. R., Carter, J. B., Carucci, J. A., Hirotsu, K. E., Koyfman, S. A., Mangold, A. R., Girardi, F. M., Shahwan, K. T., Srivastava, D., Vidimos, A. T., Willenbrink, T. J., Wysong, A., & Ruiz, E. S. (2025). Risk Factor Number and Recurrence, Metastasis, and Disease-Related Death in Cutaneous Squamous Cell Carcinoma. JAMA Dermatology, 161(6), 597. https://doi.org/10.1001/jamadermatol.2025.0128
Vancouver
Ran NA, Granger EE, Brodland DG, Cañueto J, Carr DR, Carter JB, et al. Risk Factor Number and Recurrence, Metastasis, and Disease-Related Death in Cutaneous Squamous Cell Carcinoma. JAMA Dermatology. 2025;161(6):597. doi:10.1001/jamadermatol.2025.0128
BibTeX
@article{Ran2025,
author = {Ran, Nina A and Granger, Emily E and Brodland, David G and Cañueto, Javier and Carr, David R and Carter, Joi B and Carucci, John A and Hirotsu, Kelsey E and Koyfman, Shlomo A and Mangold, Aaron R and Girardi, Fabio Muradás and Shahwan, Kathryn T and Srivastava, Divya and Vidimos, Allison T and Willenbrink, Tyler J and Wysong, Ashley and Ruiz, Emily S},
title = {Risk Factor Number and Recurrence, Metastasis, and Disease-Related Death in Cutaneous Squamous Cell Carcinoma},
journal = {JAMA Dermatology},
year = {2025},
volume = {161},
number = {6},
pages = {597},
doi = {10.1001/jamadermatol.2025.0128}
}
EUVIMED